Abstract

The prediction of in vivo clearance from in vitro metabolism models such as liver microsomes is an established procedure in drug discovery. The potentials and limitations of this approach have been extensively evaluated in the pharmaceutical sector; however, this is not the case for the field of positron emission tomography (PET) radiotracer development. The application of PET radiotracers and classical drugs differs greatly with regard to the amount of substance administered. In typical PET imaging sessions, subnanomolar quantities of the radiotracer are injected, resulting in body concentrations that cannot be readily simulated in analytical assays. This raises concerns regarding the predictability of radiotracer clearance from in vitro data. We assessed the accuracy of clearance prediction for three prototypical PET radiotracers developed for imaging the A1 adenosine receptor (A1AR). Using the half-life (t1/2) approach and physiologically based scaling, in vivo clearance in the rat model was predicted from microsomal stability data. Actual clearance could be accurately predicted with an average fold error (AFE) of 0.78 and a root mean square error (RMSE) of 1.6. The observed slight underprediction (1.3-fold) is in accordance with the prediction accuracy reported for classical drugs. This result indicates that the prediction of radiotracer clearance is possible despite concentration differences of more than three orders of magnitude between in vitro and in vivo conditions. Consequently, in vitro metabolism models represent a valuable tool for PET radiotracer development.

Highlights

  • The application of positron emission tomography (PET) as a tool for molecular neuroimaging is limited by the availability of suitable radiotracers

  • The potentials and limitations of this approach have been extensively evaluated in the pharmaceutical sector; this is not the case for the field of positron emission tomography (PET) radiotracer development

  • We assessed the accuracy of clearance prediction for three prototypical PET radiotracers developed for imaging the A1 adenosine receptor (A1AR)

Read more

Summary

Introduction

The application of PET as a tool for molecular neuroimaging is limited by the availability of suitable radiotracers. The in vivo performance of a novel compound is determined by numerous physicochemical and pharmacological factors, of which metabolism represents a important one [1]. The metabolic lability of a candidate radiotracer may lead to a rapid decrease of radiotracer plasma concentration, resulting in insufficient brain exposure. This is problematic if longer scan durations are required to properly image the molecular target. Excessive radiotracer metabolism increases the risk that brain-penetrant radiolabeled molecular target. Excessive radiotracer metabolism increases the risk that

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call